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Breech presentation is encountered in 3 to 4% of term pregnancies and has been a significant driver of the
increased rate of cesarean deliveries over the last 4 decades. External cephalic version (ECV) is recommended at
term by most professional organizations in an effort to reduce the prospect of cesarean deliveries. The authors
propose the use of regional anesthesia to increase efficacy and reduce cost in the care of patients who undergo
ECV in an effort to convert a breech presentation to a vertex counterpart. Despite emerging evidence of the
advantages, obstacles to more comprehensive implementation of this approach continue to exist, which include
patient acceptance, provider experience, and safety concerns. The addition of tocolytics and use of regional
anesthesia for secondary ECV efforts have also been considered as options to increase success and reduce cost. This
is a commentary on http://www.ijhpr.org/content/3/1/5.Commentary
The 1980’s and 90’s had seen a significant decline in the
rate of vaginal breech delivery as per observational stud-
ies and anecdotal reports. As such, this trend was facili-
tated by an increasingly litigious environment in many
parts of the world. With the publication of the Term
Breech Trial in 2000 [1] a further increase has been noted
in the prevalence of cesarean delivery for breech presenta-
tion, now as high as 98% in some populations [2]. Despite
the fact that the methodology and implications of the
Term Breech Trial have been questioned and that several
professional organizations have since endorsed breech
vaginal delivery in properly selected patients, it is unlikely
that the preference for cesarean breech delivery will abate
any time soon.
Breech presentation constitutes the third most com-
mon indication for cesarean delivery and now accounts
for approximately 15% of all cesarean sections performed
in the US at an estimated annual cost of $1.4B [3]. In an
effort to decrease the incidence of cesarean deliveries for
breech presentation, professional organizations recom-
mend offering most patients external cephalic version
(ECV) at term. Reported success rates for ECV have
ranged from 35 to 86%, with an average of 58% [4]. With* Correspondence: jobrien@wihri.org
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article, unless otherwise stated.renewed interest in this technique, considerable research
has been devoted to interventions that will improve the
success and the patient acceptance of ECV. In addition to
these efforts to reduce the overall incidence of cesarean
deliveries and their inherent morbidities, it is essential to
assess the cost of the relevant interventions to the health-
care system.
In this month’s issue of the Israel Journal of Health
Policy Research, Weiniger and colleagues evaluate the hos-
pital costs associated with alternative clinical approaches
to breech presentation [5]. In this secondary analysis of
data from two prior studies (by applying adjusted cost
data), the authors conclude that external cephalic version
under neuraxial blockade is a cost-effective approach to
the challenges presented by the breech presentation. As it
stands, the current management options for the breech
presentation in the Hassadah-Hebrew University Medical
Center, the site of their study, are the same as in most aca-
demic centers – perform ECV or proceed to an elective
cesarean section. In the study of Weiniger et al., ECV
under spinal anesthesia resulted in successful version in
76% of the cases with 84% of the women in question deliv-
ering vaginally. These results were estimated to translate
into annual cost savings to the Israeli healthcare system of
over 20 M NIS ($5.9 M). The authors also correctly point
out that healthcare costs differ greatly between countries
and that even greater potential savings could be realized
in countries wherein manpower costs are higher. Theentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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improved quality adjusted life years (QALYs) that coincide
with a reduction in cesarean delivery rates.
This report concurs with prior studies analyzing costs
associated with ECV. Using a computer-based decision
model, Tan et al. [6] concluded that from a societal per-
spective, an ECV trial was cost-effective when compared
to a scheduled cesarean section for breech presentation
provided the probability of successful ECV was greater
than 32%. Gifford et al. [7], in turn, using decision-analysis
techniques, demonstrated a decrease in the cesarean deliv-
ery rate as well as cost savings for patients delivering
after unsuccessful versions by scheduled cesarean delivery
versus routinely scheduling a cesarean when a breech
presentation is identified at term.
The data cited in this study represents a compilation
of two previous publications by the author. The prospect-
ive randomized controlled trials in question each revealed
significantly increased rates of successful ECV in nullipar-
ous and multiparous populations using spinal anesthesia.
The initial study [8], carried out in nulliparous patients,
demonstrated successful ECV in 66.7% of patients receiv-
ing spinal anesthesia versus 32.4% in untreated counter-
parts. The study of multiparous patients [9] also showed a
significant success with spinal anesthesia (87.1%) versus
without such intervention (57.5%). Both studies docu-
mented a significant decrease in visual analogue pain
scores in patients receiving spinal anesthesia. The findings
of these two smaller studies were confirmed in a meta-
analysis [10] that included 4 additional randomized con-
trolled trials.
Although the case for increased success and reduced
costs for ECV is clear, some concerns and controversy
remain. Patient acceptance has not been universal with
reported rates of maternal refusal of an ECV attempt ran-
ging from 18 to 76% [11]. In their vignette study Vlemmix
et al. [12] showed that expected procedural pain and the
success rate thereof were the most important factors influ-
encing patient willingness to undergo ECV. The use of
regional anesthesia would seem to satisfy both of these
concerns. Provider experience and comfort level may also
impact utilization as 4 to 33% of patients suitable for ECV
were not offered the procedure [11]. In situations wherein
provider reluctance due to inexperience is the case, it may
be reasonable and advantageous for institutions to con-
sider offering the services of more experienced providers
to perform ECV.
ECV is felt to be a safe procedure. However, safety
concerns are still raised in some reports. Although most
of the controversy dates back to 1970 when procedure-
associated fetal mortality was thought to be about 1%,
the following is worth considering. The most frequent
complication of ECV is transient fetal heart rate changes
that have been reported in 5.7% of cases [13]. Persistentchanges resulting in the need for emergency cesarean
delivery are seen only in 0.3% of cases. The incidence of
placental abruption is 0.12% and the prevalence of
feto-maternal transfusion appears to range from 2 to 4%.
Opponents of the use of anesthesia for ECV argue that
complication rates are higher under these circumstances
and feel that this may be related to the potential of
applying too much force in these pain-free patients.
Other medications have also been used to enhance the
success of ECV. Randomized trials have demonstrated
that significant improvement may be expected with most
tocolytics with the exception of nifedipine. These medi-
cations have been used in conjunction with regional
anesthesia in some studies and likely provide a combin-
ation of myometrial and abdominal muscular relaxation.
The combined use of a tocolytic and regional anesthesia
appears to be associated with an increased success rate.
The literature regarding the use of regional anesthesia
features studies using spinal, epidural, and combined
spinal epidural approaches. Most studies seek to achieve
adequate anesthesia to the T6 level which may well
optimize the likelihood for successful ECVs. Several au-
thors emphasize the difference in using anesthesia versus
analgesic dosing levels as a key to successful ECV as well.
Some also favor the use of combined spinal epidural as a
means to providing adequate dosing for an emergency
cesarean delivery in the event of a non-resolving fetal
bradycardia.
Many authors have tried to define predictors of a suc-
cessful ECV with little consistency. In a comprehensive
meta-analysis [11] involving over 10,000 women, multi-
parity, non-engagement of the breech, a relaxed uterus,
a palpable fetal head, and maternal weight less than 65 kg
were shown to be valid positive prognostic indicators.
Smaller studies have assessed alternative approaches
using neuraxial anesthesia as a secondary option after
an unsuccessful attempted version without anesthesia.
Rozenberg et al. [14] resorting to epidural anesthesia re-
ported a 39.7% success rate for ECV after an unsuccess-
ful initial attempt with a beta-mimetic alone. Their
overall success rate was 72.8%. This approach may well
have the potential to yield additional cost savings.
Successful ECV does not guarantee a vaginal delivery.
Spontaneous reversion to the breech presentation can
occur in approximately 4% of cases. More significantly,
cesarean delivery is more than twice as likely in patients
after ECV than in control patients with cephalic presen-
tations [15]. The main indications for the cesarean de-
liveries in question are dystocia and fetal intolerance of
labor. Although several hypotheses have been advanced
for these findings, the reasons remain unclear. Kabiri
et al. [16] observed in a retrospective cohort study that
the risk of cesarean delivery was significantly decreased
when delivery occurred more than 96 hours after
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patients.
With cesarean section currently considered as the only
delivery option for breech presentation in many settings,
efforts to optimize successful external cephalic version
will likely assume increased significance. It follows that
institutions should consider strategies to gain better pa-
tient and provider acceptance and enhance the rates of
success. The use of tocolytics and regional anesthesia
has been consistently shown to increase ECV success.
The study by Weiniger and colleagues demonstrates the
additional benefit of decreased costs with this thera-
peutic strategy.
This is a commentary on Weiniger CF, Spencer PS,
Weiss Y, Ginsberg G, Ezra Y. Secondary data analysis of
hospital costs for external cephalic version under neur-
axial blockade to reduce cesarean delivery for breech
presentation at term. Israel Journal of Health Policy
Research 2014;3:5.
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